臨床泌尿器科77巻11号

2023年10月発行

特集 どうする! 前立腺癌―多彩な治療薬をどう上手く使うか

〈mCSPCの薬物治療〉

mCSPCに対するアビラテロンによるup-front治療

著者： 内木拓¹ 安井孝周¹

所属機関： ¹名古屋市立大学大学院医学研究科腎・泌尿器科学分野

ページ範囲：P.848 - P.852

文献概要

▶ポイント

・アビラテロンによるup-front治療は，本邦でこれまで行われてきたアンドロゲン遮断療法（CAB）よりも予後に寄与する．

・up-front治療が主流の現在においても，去勢抵抗性前立腺癌（CRPC）までの期間をより長くすることが，全生存率の延長に寄与する．

・今後はup-frontアビラテロン治療の間欠療法のデータ集積が期待される．

参考文献

1） Clarke NW, et al : Addition of Docetaxel to Hormonal Therapy in Low-And High Burden Metastatic Hormone Sensitive Prostate Cancer : Long-Term Survival Results from the STAMPEDE Trial. Ann Oncol 30 : 1992-2003, 2019

2） Fizazi K, et al : Abiraterone Acetate plus Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer （LATITUDE） : Final Overall Survival Analysis of a Randomized, Double-Blind, Phase 3 Trial. Lancet Oncol 20 : 686-700, 2019

3） Armstrong AJ, et al : ARCHES : A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. J Clin Oncol 37 : 2974-2986, 2019

4） Chi KN, et al : Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer : Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. J Clin Oncol 39 : 2294-2303, 2021

5） 内木 拓, 他 : mHSPCに対するupfront治療におけるリアルワールドデータ. 泌外35 : 1031-1035, 2022

6） Ueda T, et al : Abiraterone Acetate versus Bicalutamide in Combination with Gonadotropin Releasing Hormone Antagonist Therapy for High Risk Metastatic Hormone Sensitive Prostate Cancer. Sci Rep 11 : 10094, 2021

7） Yanagisawa T, et al : Abiraterone Acetate versus Nonsteroidal Antiandrogen with Androgen Deprivation Therapy for High-Risk Metastatic Hormone-Sensitive Prostate Cancer. Prostate 82 : 3-12, 2022

8） Matsumura N, et al : Comparison of Abiraterone and Combined Androgen Blockade Therapy for High-Risk Metastatic hormone-Sensitive Prostate Cancer : A Propensity Score-Matched Analysis. Front Oncol 11 : 769068, 2021

9） Narita S, et al : Real-World Survival Outcomes of Adding Docetaxel or Abiraterone in Patients with High-Volume Metastatic Castration-Sensitive Prostate Cancer : Historically Controlled, Propensity Score Matched Comparison with Androgen Deprivation Therapy. World J Urol 40 : 1135-1141, 2022

10） Naiki T, et al : Comparison of Clinical Outcomes Between Androgen Deprivation Therapy with Up-Front Abiraterone and Bicalutamide for Japanese Patients with LATITUDE High-Risk Prostate Cancer in a Real-World Retrospective Analysis. Int J Clin Oncol 27 : 592-601, 2022

11） Miyake H, et al : Prognostic Significance of Time to Castration Resistance in Patients with Metastatic Castration-Sensitive Prostate Cancer. Anticancer Res 39 : 1391-1396, 2019

12） Matsubara N, et al : Correlation of Prostate-specific Antigen Kinetics with Overall Survival and Radiological Progression-free Survival in Metastatic Castration-sensitive Prostate Cancer Treated with Abiraterone Acetate Plus Prednisone or Placebos Added to Androgen Deprivation Therapy : Post Hoc Analysis of Phase 3 LATITUDE Study. Eur Urol 77 : 494-500, 2020

13） Suzuki H, et al : Efficacy and Safety of Abiraterone Acetate Plus Prednisone in Japanese Patients with Newly Diagnosed, Metastatic Hormone-Naive Prostate Cancer : Final Subgroup Analysis of LATITUDE, a Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study. Jpn J Clin Oncol 50 : 810-820, 2020

14） Zhang J, et al : A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer. Cancers （Basel） 14 : 5225, 2022

Metastatic Castration-Sensitive Prostate Cancer. Clin Cancer Res 28 : 4917-4925, 2022